YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
List view / Grid view
Filter the results
Researchers have demonstrated that bioavailability tests in patients to reveal anti-drug antibody levels could aid personalised medicine.
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review...